CN105025891B - Hmb和atp的组合物及使用方法 - Google Patents

Hmb和atp的组合物及使用方法 Download PDF

Info

Publication number
CN105025891B
CN105025891B CN201380058560.6A CN201380058560A CN105025891B CN 105025891 B CN105025891 B CN 105025891B CN 201380058560 A CN201380058560 A CN 201380058560A CN 105025891 B CN105025891 B CN 105025891B
Authority
CN
China
Prior art keywords
hmb
atp
animal
administration
strength
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380058560.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105025891A (zh
Inventor
S·拜尔
L·科尔布
J·拉特马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiyuan Group Co ltd
Original Assignee
Tsi Co ltd
Metabolic Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsi Co ltd, Metabolic Technologies LLC filed Critical Tsi Co ltd
Publication of CN105025891A publication Critical patent/CN105025891A/zh
Application granted granted Critical
Publication of CN105025891B publication Critical patent/CN105025891B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380058560.6A 2012-09-10 2013-09-10 Hmb和atp的组合物及使用方法 Active CN105025891B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698919P 2012-09-10 2012-09-10
US61/698,919 2012-09-10
PCT/US2013/059039 WO2014040067A1 (en) 2012-09-10 2013-09-10 Composition of hmb and atp and methods of use

Publications (2)

Publication Number Publication Date
CN105025891A CN105025891A (zh) 2015-11-04
CN105025891B true CN105025891B (zh) 2020-01-21

Family

ID=50237697

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380058560.6A Active CN105025891B (zh) 2012-09-10 2013-09-10 Hmb和atp的组合物及使用方法

Country Status (14)

Country Link
US (1) US10092590B2 (https=)
EP (2) EP2892522A4 (https=)
JP (1) JP6258943B2 (https=)
CN (1) CN105025891B (https=)
AU (1) AU2013312113B2 (https=)
BR (1) BR112015005199B1 (https=)
CA (1) CA2884405C (https=)
DK (1) DK3733171T3 (https=)
ES (1) ES2970283T3 (https=)
FI (1) FI3733171T3 (https=)
HU (1) HUE065064T2 (https=)
PL (1) PL3733171T3 (https=)
PT (1) PT3733171T (https=)
WO (1) WO2014040067A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121177244A (zh) * 2016-05-25 2025-12-23 技源集团股份有限公司 包含3-羟基-3-甲基丁酸的软凝胶胶囊剂
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
WO2022271813A1 (en) * 2021-06-22 2022-12-29 Tsi Usa, Llc Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261238A1 (en) * 2001-06-04 2005-11-24 Lee Steve S Method for increasing muscle mass and strength through administration of adenosine triphosphate
WO2006034586A1 (en) * 2004-09-29 2006-04-06 Aplodan Formulations Ltd. Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker
US20120053240A1 (en) * 2009-12-18 2012-03-01 Metabolic Technologies, Inc. Method of Administering beta-hydroxy-beta-methylbutyrate (HMB)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028440A (en) 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
FI951218A0 (fi) 1992-09-16 1995-03-15 Univ Iowa State Res Found Inc Menetelmä kokonaiskolesterolin ja matalatiheyksisen lipoproteiinikolestrolin pitoisuuksien pienentämiseksi veressä
US5348979A (en) 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
JP4010390B2 (ja) 1999-09-20 2007-11-21 明治乳業株式会社 免疫賦活化組成物
US20050027005A1 (en) 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20060073891A1 (en) * 2004-10-01 2006-04-06 Holt Timothy M Display with multiple user privacy
CN101184496A (zh) 2005-05-27 2008-05-21 兴和株式会社 用于恢复疲劳的药品
WO2007108071A1 (ja) 2006-03-17 2007-09-27 Pharma Foods International Co., Ltd. 抗ストレス組成物及びそれを含有する飲食品
CA2746420C (en) 2008-12-09 2019-11-12 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
DE102009052640A1 (de) 2009-11-10 2011-05-12 Linde-Lkca-Dresden Gmbh Verfahren und Vorrichtung zur Gaswäsche

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261238A1 (en) * 2001-06-04 2005-11-24 Lee Steve S Method for increasing muscle mass and strength through administration of adenosine triphosphate
WO2006034586A1 (en) * 2004-09-29 2006-04-06 Aplodan Formulations Ltd. Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker
US20120053240A1 (en) * 2009-12-18 2012-03-01 Metabolic Technologies, Inc. Method of Administering beta-hydroxy-beta-methylbutyrate (HMB)

Also Published As

Publication number Publication date
FI3733171T3 (fi) 2024-01-24
JP2015527408A (ja) 2015-09-17
DK3733171T3 (da) 2024-01-29
EP3733171B1 (en) 2023-10-25
HK1217087A1 (zh) 2016-12-23
WO2014040067A1 (en) 2014-03-13
US20140080781A1 (en) 2014-03-20
EP2892522A4 (en) 2016-01-20
EP3733171A1 (en) 2020-11-04
JP6258943B2 (ja) 2018-01-10
US10092590B2 (en) 2018-10-09
HUE065064T2 (hu) 2024-05-28
EP2892522A1 (en) 2015-07-15
CA2884405C (en) 2021-03-30
BR112015005199A2 (pt) 2017-07-04
PT3733171T (pt) 2024-01-31
BR112015005199B1 (pt) 2022-09-06
AU2013312113B2 (en) 2018-08-02
CN105025891A (zh) 2015-11-04
CA2884405A1 (en) 2014-03-13
PL3733171T3 (pl) 2024-03-18
ES2970283T3 (es) 2024-05-27
AU2013312113A1 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
Fitschen et al. Efficacy of β-hydroxy-β-methylbutyrate supplementation in elderly and clinical populations
Legault et al. The influence of oral L-glutamine supplementation on muscle strength recovery and soreness following unilateral knee extension eccentric exercise
US20190209501A1 (en) Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) assosiated with intermittent fasting
JP5762396B2 (ja) 糖尿病療法の支援のためのα−ケト酸を含有する栄養補助剤
Molsted et al. The effects of high-load strength training with protein-or nonprotein-containing nutritional supplementation in patients undergoing dialysis
CN105025891B (zh) Hmb和atp的组合物及使用方法
CA2900526C (en) Compositions and their use to treat heart failure with preserved injection fraction (hfpef)
Stevens et al. Exercise improves cardiac function and attenuates insulin resistance in Dahl salt-sensitive rats
US10888576B2 (en) Composition of HMB and ATP and methods of use
JP2022546843A (ja) アデノシン三リン酸（ａｔｐ）を含有する組成物及び使用方法
McDonough Oral creatine hydrochloride supplementation: acute effects on submaximal, intermittent bouts of bench press and vertical jump exercises
HK1217087B (zh) Hmb和atp的组合物及使用方法
US20160184248A1 (en) Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
Kawecka et al. Creatine supplementation: facts and myths
Turpin Therapeutic role of dietary nitrates on cardiorespiratory function in cancer survivors
JP2013510126A (ja) コリン含有医薬組成物
Fischer Reduced endothelial and exercise vasodilator function in the legs of obese versus lean and overweight Postmenopausal women
McNeal et al. The role of arginine for treating obese youth
Clarke Impact of Creatine Supplementation on Vascular Endothelial Function, Blood Flow and Functional Capacity in Older Adults
Boldt et al. A high-whey-protein diet does not enhance mechanical and structural remodeling of cardiac muscle in response to aerobic exercise in rats
Demaison et al. Is there an ‘obesity paradox’of cardiac survival in heart disease? A perspective from experimental laboratory studies
Fitschen Efficacy of beta-hydroxy-beta-methylbutyrate (HMB) supplementation in hemodialysis patients
Stevens et al. Exercise improves cardiac function and insulin resistance in Dahl salt-sensitive rats

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1217087

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Iowa, USA

Patentee after: Metabolic Technologies LLC

Patentee after: TSI Co.,Ltd.

Address before: Iowa, USA

Patentee before: METABOLIC TECHNOLOGIES, Inc.

Patentee before: TSI Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220812

Address after: Iowa, USA

Patentee after: Metabolic Technologies LLC

Address before: Iowa, USA

Patentee before: Metabolic Technologies LLC

Patentee before: TSI Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231121

Address after: No. 2 Jinxiu Road, Jiangyin Lingang Economic Development Zone, Wuxi City, Jiangsu Province

Patentee after: Jiyuan Group Co.,Ltd.

Address before: Iowa, USA

Patentee before: Metabolic Technologies LLC